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Inflammation plays a key role in dry eye disease (DED) affecting millions of people worldwide. Non-
steroidal anti-inflammatory drugs (NSAIDs) can be used topically to act on the inflammatory 
component of DED, but their limited aqueous solubility raises formulation issues. The aim of this 
study was development and optimization of functional cationic nanoemulsions (NEs) for DED 
treatment, as a formulation approach to circumvent solubility problems, prolong drug residence at 
the ocular surface and stabilize the tear film. Ibuprofen was employed as the model NSAID, chitosan 
as the cationic agent, and lecithin as the anionic surfactant enabling chitosan incorporation. 
Moreover, lecithin is a mixture of phospholipids including phosphatidylcholine and 
phosphatidylethanolamine, two constituents of the natural tear film important for its stability. NEs 
were characterized in terms of droplet size, polydispersity index, zeta-potential, pH, viscosity, 
osmolarity, surface tension, entrapment efficiency, stability, sterilizability and in vitro release. NEs 
mucoadhesive properties were tested rheologically after mixing with mucin dispersion. 
Biocompatibility was assessed employing 3D HCE-T cell-based model and ex vivo model using 
porcine corneas. The results of our study pointed out the NE formulation with 0.05 % (w/w) chitosan 
as the lead formulation with physicochemical properties adequate for ophthalmic application, 
mucoadhesive character and excellent biocompatibility. 
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A stable preocular tear film is a hallmark of ocular health, as it protects and moisturizes cornea and 
forms the primary refracting surface for light entering the visual system (Willcox et al., 2017). A two 
layered model of the tear film has been proposed, consisting of: (i) a mucoaqueous gel layer making 
up the bulk of the tear thickness and interacting directly with the epithelium, and (ii) an overlying 
very thin lipid layer, at least partly integrated with the mucoaqueous gel. Dry eye disease (DED), a 
multifactorial disease of the ocular surface, is characterized by a loss of homeostasis of the tear film 
(Craig et al., 2017). The loss of homeostasis involves a quantitative or qualitative deficiency of tears 
that typically induces tear film instability, wetting defects and hyperosmolar stress, increased friction 
and chronic mechanical irritation at the ocular surface (Bron et al., 2017). This initiates a chain of 
inflammatory events and further ocular surface damage. 
Currently, the main therapeutic options for DED are tear replacement and topical anti-inflammatory 
therapy (Jones et al., 2017). A topical ophthalmic formulation with or without an active 
pharmaceutical ingredient (API) is delivered directly on the ocular surface and excipients used in the 
formulation play an essential role in addressing quantitative or qualitative deficiency of tears. There 
are numerous over-the-counter products (artificial tears) aiming to replace and/or supplement the 
tear film. The most abundant component in these lubricant eye drops is the aqueous base with a 
variety of viscosity enhancing agents incorporated to improve lubrication and prolong the retention 
time on the ocular surface. More recently, a variety of lipids (e.g. mineral oils and phospholipids) 
have been incorporated in ocular lubricant formulations to help restoration of the tear film lipid 
layer (Benelli, 2011). APIs aiming at decreasing inflammation at the ocular surface include 
glucocorticoids, non-glucocorticoid immunomodulators (i.e. cyclosporine A (CsA) and tacrolimus), 
non-steroidal anti-inflammatory drugs (NSAIDs) and antibiotics (Jones et al., 2017).  
Oil-in-water (O/W) nanoemulsions (NEs), ultrafine dispersions stabilized by an amphiphilic surfactant 
(Singh et al., 2017), hold great potential for effective treatment of DED (Jones et al., 2017; Lallemand 
et al., 2017). According to current understanding, mixing of a NE with the tear film compromises NE 
stability, the oil nanodroplets break down with time, the oil merges with the lipid layer of the tear 
film, and the surfactant components associate with the mucus layer (Gan et al., 2013; Walenga et al., 
2019). Supplementation of a deficient tear film lipid layer (TFLL) with appropriate lipid components 
by merging with oil droplets possibly induces tear film stabilization. Furthermore, NEs effectively 
deliver APIs with limited aqueous solubility into the corneal segment giving delayed and sustained 
release (Lalu et al., 2017). This can be ascribed to oil nanodroplets that act as an API reservoir before 
and after merging with TFLL. As the majority of anti-inflammatory APIs have limited aqueous 
solubility, API-loaded NE can assure dry eye symptom relief due to tear film stabilization as well as 
anti-inflammation effects breaking the vicious circle of DED.  
Over the past two decades NEs have been seriously investigated as a strategy to enhance the eye-
related bioavailability of CsA following topical ocular instillation (Lallemand et al., 2017). These 
efforts led to the commercialization of three NE-based ophthalmic products for treatment of DED. 
Restasis® (Allergan) is a preservative-free anionic O/W NE of CsA-loaded castor oil, emulsified and 
stabilized by polysorbate 80 and carbomer copolymer, approved by the U.S. Food and Drug 
Administration (FDA). Lacrinmune® (Bausch & Lomb, approved in Argentina) has a composition 
similar to that of Restasis®, except for the addition of sodium hyaluronate which increases 
formulation viscosity with the aim to prolong the residence time at the ocular surface. Ikervis® 
(Santen) is a cationic NE of medium-chain triglycerides emulsified and stabilized using tyloxapol, 
poloxamer 188 and cetalkonium chloride, approved by the European Medicines Agency (EMA). In 
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this formulation quaternary ammonium cetalkonium chloride, an alkyl derivative of benzalkonium 
chloride, does not have a preservative role but it renders the oil nanodroplets positively charged. 
The presence of positive charge on the nanodroplet surface enables their electrostatic interaction 
with negatively charged ocular surface mucins, improving formulation precorneal residence (Daull et 
al., 2014). It is therefore assumed that the residence time of CsA in Ikervis® is longer than that in 
Restasis® (Lallemand et al., 2012), which, accompanied with higher dosage strength, could very likely 
explain the difference in dosing regimen between once-a-day Ikervis® versus twice-a-day Restasis® 
(Lallemand et al., 2017). 
CsA is used in the treatment of more severe cases of DED; it has to be used for extended periods of 
time and its onset of action is postponed. Topical corticosteroid or NSAID short-term pre-treatment 
could provide faster sign and symptom relief than topical CsA alone in severe DED (Jones et al., 
2017). Moreover, topical glucocorticoids or NSAIDs have a potential for effective treatment of mild-
to-moderate DED. Development of formulations with prolonged residence at the ocular surface 
would enable reduction of the required dose of glucocorticoids and NSAIDs providing better benefit-
risk balance of future ophthalmic drug products (Subrizi et al., 2019). Therefore, further 
investigations are needed to explore the potential of glucocorticoids or NSAIDs in a pulse-dose form 
to break the vicious circle of DED, to develop effective formulations and to clarify the appropriate 
dosing schedules. 
In this study, we propose the development of a functional cationic ophthalmic NE loaded with a 
NSAID aiming to relieve dryness, stabilize the tear film and act on the inflammatory component in 
mild-to-moderate DED patients. Special attention was paid to the selection of excipients in order to 
achieve optimal balance between formulation properties (droplet size and size distribution, zeta-
potential, osmolarity, viscosity, surface tension and stability) and formulation effect on the ocular 
surface (mucoadhesion, tear film and corneal epithelium biocompatibility). The mucoadhesive 
biopolymer chitosan was chosen as a carrier of positive charge and was incorporated in NE using its 
interaction with the anionic surfactant lecithin. Lecithin is a natural lipid mixture of phospholipids 
including phosphatidylcholine and phosphatidylethanolamine, two phospholipids that are commonly 
found in tears (Dean and Glasgow, 2012; Jones et al., 2017; Saville et al., 2011). Kolliphor® EL, a non-
ionic surfactant commonly used in ophthalmic products, was used as the second (more hydrophilic) 
surfactant to optimize the NE droplet size and stability (Trotta et al., 2002). Ibuprofen was used as 
the model NSAID of highly lipophilic nature. The formulation biocompatibility assessment employing 






2. Materials and methods 
 
2.1. Materials 
Ibuprofen (Hubei Biocause Phamaceutical Co., Ltd., Jingmen, China) was kindly donated by Pliva 
(Zagreb, Croatia). For NE preparation the following substances were used: Miglyol® 812 (Kemig, 
Zagreb, Croatia), lecithin (Lipoid S 45, Lipoid, Ludwigshafen, Germany), Kolliphor® EL (BASF, 
Ludwigshafen, Germany), glycerol (T.T.T., Sveta Nedjelja, Croatia), low molecular weight (Mw) 
chitosan (Mw range 50-190 kDa, degree of deacetylation range 75-85 % and viscosity range of 1 % 
(w/w) solution in 1 % acetic acid 20-300 mPas; Sigma-Aldrich, Steinheim, Germany) and medium Mw 
chitosan (Mw range 190-310 kDa, degree of deacetylation range 75-85 % and viscosity range of 1 % 
(w/w) solution in 1 % acetic acid 200-800 mPas; Sigma-Aldrich). Porcine gastric mucin type II was 
purchased from Sigma-Aldrich and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT) was purchased from AppliChem (Darmstadt, Germany). Fluorescein sodium salt was 
purchased from Sigma-Aldrich, HEPES from AppliChem, Na2HPO4×2H2O from Fluka Chemie AG 
(Buchs, Switzerland). All other reagents were of analytical grade and purchased from Kemig or 
Sigma-Aldrich. Simulated tear fluid (STF) pH 7.4 was prepared by dissolving KCl (1.4 mg mL-1), NaCl 
(6.8 mg mL-1), NaHCO3 (2.2 mg mL
-1) and CaCl2×2H2O (0.08 mg mL
-1) in double-distilled water. Hank's 
balanced salt solution (HBSS) pH 6.0 was prepared by dissolving KCl (0.4 mg mL-1), NaHCO3 (0.35 mg 
mL-1), NaCl (8.0 mg mL-1), D-glucose monohydrate (1.1 mg mL-1), KH2PO4 (0.06 mg mL
-1), 
Na2HPO4×2H2O (0.06 mg mL
-1), CaCl2×2H2O (0.185 mg mL
-1), MgCl2×6H2O (0.1 mg mL
-1), MgSO4×7H2O 
(0.1 mg mL-1) and HEPES (7.15 mg mL-1) in double-distilled water. Krebs-Ringer buffer (KRB) pH 7.4 
was prepared by dissolving KCl (0.4 mg mL-1), NaCl (6.8 mg mL-1), NaHCO3 (2.1 mg mL
-1), 
MgSO4×7H2O (0.4 mg mL
-1), D-glucose monohydrate (1.1 mg mL-1), CaCl2×2H2O (0.52 mg mL
-1), 
NaH2PO4×2H2O (0.158 mg mL
-1) and HEPES (3.575 mg mL-1) in double-distilled water. 
 
2.2. Solubility study 
The solubility of ibuprofen in Miglyol® 812 and lecithin/Miglyol® 812 (1:50, w/w) solution was 
determined by adding an excess amount of drug to 5 g of oil or lecithin solution in oil and 
subsequent magnetic stirring at 25 °C during 48 h to reach equilibrium. Afterwards, the samples 
were centrifuged for 30 min at 1520  g and the supernatants filtered through 0.2 µm Spartan™ 
regenerated cellulose filters (Whatman, United Kingdom). The samples were further diluted with 
methanol and ibuprofen concentration was analyzed using Ultra-Performance Liquid 
Chromatography (UPLC), as described in the section 2.13. 
 
2.3. Nanoemulsion preparation 
 
2.3.1. Nanoemulsions with lecithin and Kolliphor® EL 
NEs with 5 % (w/w) Miglyol® 812 and increasing amounts of lecithin (0.1-1.0 %, w/w) were prepared 
using microfluidizer (Model M-110EH-30, Microfluidics®, Westwood, MA, USA). Before 
homogenization lecithin was dissolved in Miglyol® 812 at room temperature (RT) under magnetic 
stirring. Lecithin solution in Miglyol® 812 (oil phase) was added to water phase under magnetic 
stirring, and the mixture was further pre-homogenized with Ultra-Turrax® (IKA-Werke GmbH & 
Company, Staufen, Germany) during 5 min at 6000 rpm. The obtained coarse emulsion was then 
processed with microfluidizer under the pressure of 1000 bar and 10 cycles. 
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NEs with 5 % (w/w) Miglyol® 812, 0.1 % (w/w) lecithin and increasing amounts of Kolliphor® EL (0.25-
2.5 %, w/w) were prepared as described above using the water phase containing Kolliphor® EL. 
Process parameters (pressure and number of cycles) were optimized on a coarse O/W emulsion 
containing 5 % (w/w) Miglyol® 812, 0.1 % (w/w) lecithin and 0.5 % (w/w) Kolliphor® EL. The pressure 
and the number of cycles were varied in the range 400-1300 bar and 1-15, respectively. NE with the 
same composition was also prepared using high-pressure homogenizer (Panda Plus 2000®, GEA Niro 
Soavi, Parma, Italy) under the pressure of 1000 bar and 5 cycles. 
 
2.3.2. Chitosan-coated nanoemulsions 
Chitosan-coated NEs were prepared with two different methods using increasing amounts of low 
(LMw) or medium (MMw) Mw chitosan. In the first method, optimized uncoated NE prepared using 
microfluidizer (1000 bar, 5 cycles) was magnetically stirred with different amounts of 1 % (w/w) 
chitosan (LMw or MMw) solution (filtered, prepared in 0.5 %, w/w acetic acid). The final chitosan 
concentration ranged from 0.05 to 0.5 % (w/w) while the concentration of Miglyol® 812 was fixed at 
2.5 % (w/w). In the second method, different amounts of 1 % (w/w) chitosan (LMw) solution were 
added to the aqueous Kolliphor® EL solution (water phase) prior phase mixing and processing on 
microfluidizer (1000 bar, 5 cycles). The final chitosan concentration in NEs was 0.05 and 0.3 % (w/w) 
and the concentration of Miglyol® 812 was again fixed at 2.5 % (w/w). 
 
2.3.3. Ibuprofen-loaded nanoemulsions 
Ibuprofen-loaded chitosan-coated and uncoated NEs were prepared by dissolving ibuprofen (0.2 %, 
w/w) in the oil phase (lecithin solution in Miglyol® 812) at RT under magnetic stirring. Glycerol (2.5 
%, w/w) was added to the water phase to adjust NE tonicity. Uncoated ibuprofen-loaded NE was 
prepared as described above, using microfluidizer (1000 bar, 5 cycles). Chitosan-coated ibuprofen-
loaded NEs were prepared using the second method described in the section 2.3.2. 
 
2.4. Droplet size, size distribution and zeta-potential analysis 
Droplet size, polydispersity index (PDI) and zeta-potential of NEs were measured by photon 
correlation spectroscopy (PCS) using Zetasizer Ultra (Malvern Instruments, Malvern, United 
Kingdom) at 25 °C. For that purpose NE samples were diluted 500 (droplet size and PDI) and 100 
(zeta-potential) times with 0.45 µm filtered double-distilled water and 10 mM NaCl solution, 
respectively. The detection angle used for droplet size and PDI measurement was 90°. A disposable 
folded capillary cell (DTS1070) was used for zeta-potential measurement. 
 
2.5. Morphological analysis 
Atomic force microscopy (AFM) was employed to determine the morphological properties and to 
confirm data obtained on droplet size and PDI by PCS. AFM was performed using AutoProbe CP-
Research SPM (TM Microscopes-Bruker) with 90 µm large area scanner. Formulations were diluted 
with ultra-pure water 500 times (V/V), 10 µL of diluted sample was placed on circular mica substrate 
(Highest Grade V1 AFM Mica Discs, Ted Pella Inc., Redding, CA, USA) and dried in vacuum. Due to the 
nature of the samples, noncontact mode was applied. AFM measurements were performed in air, 
using noncontact probes Bruker Phosphorous doped silicon Tap300, model MPP-11123-10 with Al 
reflective coating and symmetric tip. Driving frequency of the cantilever was about 300 kHz. Both 
topography and “error signal” AFM images were taken and later analyzed using the software Image 




2.6. pH, osmolarity and surface tension 
The pH of NEs was determined using a Seven Multi pH/conducto-meter (Mettler Toledo, Columbus, 
OH, USA) at 25 °C. Osmolarity was determined by freezing point depression method (Advanced® 3D3 
Single-Sample Osmometer, Advanced Instruments, Norwood, MA, USA). The surface tension 
measurements were performed with Krüss K-100C tensiometer (Hamburg, Germany). Surface 
tension values were determined employing Du Noüy ring method. All the measurements were made 
in triplicate at 25 °C using water circulating bath with temperature stability within 0.02 °C. 
 
2.7. Ibuprofen entrapment efficiency 
The amount of ibuprofen entrapped in the oil droplets was determined by ultrafiltration. A 2 mL 
aliquot of ibuprofen-loaded NE was transferred to the upper chamber of a centrifuge tube fitted 
with ultrafilter (Centricon®, NMWL 10 kDa, Merck-Millipore, Billerica, MA, USA), which was then 
centrifuged at 5000  g for 1 h. The entrapment efficiency (EE %) was calculated from the following 
equation: 
 
EE % = 
     
  
     Eq. (1), 
 
where Wt is the total amount of ibuprofen in the NE and Wf is the amount of ibuprofen in the 
filtrate, which was determined by UPLC, as described in the section 2.13. 
 
2.8. Stability studies 
NEs were stored for 30 days at 4 and 25 °C, after which droplet size, PDI, zeta-potential and pH were 
measured to evaluate stability. Stress tests (heating-cooling cycles, centrifugation and freeze-thaw 
cycles) were performed as previously described (Shafiq et al., 2007). Six cycles between 4 and 45 °C 
were done with storage at each temperature not less than 48 h. Centrifugation was performed at 
9000 × g during 30 min. In the end, NEs were subjected to three freeze-thaw cycles between -20 and 
25 °C with storage at each temperature not less than 48 h. After each cycle or centrifugation NEs 
were examined visually for phase separation and characterized in terms of droplet size, PDI and 
zeta-potential to evaluate stability. For each of the stress tests freshly prepared NE formulations 
were used. 
 
2.9. Nanoemulsion sterilization 
NEs were aseptically filtered through 0.2 μm polyethersulfone (PES) filter or autoclaved at 121 °C for 
20 min. After each sterilization process NEs were examined visually for phase separation and 
characterized in terms of droplet size, PDI and zeta-potential. 
 
2.10. In vitro ibuprofen release 
In vitro ibuprofen release was determined using US Pharmacopeia apparatus type II (708-DS 
Dissolution Apparatus, Agilent Technologies, Santa Clara, CA, USA) modified by the addition of a 
cellulose acetate dialysis bag (Spectra/Por1 4 Dialysis Tubing, MWCO 12–14 kDa, Medicell 
International Ltd, London, UK). NE sample (1 mL) was placed in the dialysis bag, the bag was sealed 
and tied to the apparatus paddle and immersed in 900 mL of phosphate buffer pH 7.4 (34 °C, 50 
rpm). At scheduled time intervals, 2 mL aliquots were withdrawn and replaced with fresh dissolution 
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medium. The samples (including donor compartments at the end of the experiment) were analyzed 
for ibuprofen content by UPLC method, as described in the section 2.13. All experiments were 
performed at least in triplicate. 
 
2.11. Mucoadhesive properties 
NE mucoadhesive properties were determined by a slightly modified simple rheological method 
(Hassan and Gallo, 1990) using MCR 102 rheometer (Anton Paar, Graz, Austria) equipped with a 
cone-plate measuring device (CP 50-1, trim position 102 µm). For this purpose a 20 % (w/w) mucin 
dispersion in STF was prepared by overnight magnetic stirring at RT. Mucin dispersion (10 %, w/w) 
with or without NE was prepared by the addition of NE or water in 1:1 (w/w) ratio in the 20 % (w/w) 
mucin dispersion in STF. The resulting mixtures were magnetically stirred at 750 rpm during 15 min, 
and subsequently left without stirring for 1 h at RT before measurement. NEs mixed with STF in 1:1 
(w/w) ratio were prepared in the same way. Flow curves of all samples were measured at the shear 
rate range 0.1-100 s-1 and 34 °C. To calculate the viscosity component due to bioadhesion (ηb) 
viscosity values at the shear rate of 100 s-1 were used and ηb was calculated from the equation: 
 
ηb = ηt - ηm - ηn Eq. (2), 
 
where ηt is viscosity of the measured sample, ηm viscosity of 10 % (w/w) mucin dispersion and ηn 
viscosity of NE mixed with STF in 1:1 (w/w) ratio. All measurements were performed in triplicate. 
 
2.12. Biocompatibility studies 
 
2.12.1. In vitro corneal biocompatibility 
Human corneal epithelial cells (HCE-T, RIKEN Cell Bank, Tsukuba, Japan) were used for cultivation of 
3D HCE-T cell-based model as previously described (Juretic et al., 2017). Briefly, Transwell® 
polycarbonate membrane cell culture inserts (0.4 μm pore size, 12 mm diameter, surface area 1.12 
cm2, Corning B.V. Life Sciences, Amsterdam, The Netherlands) were coated with rat tail type I 
collagen (225 μg per well; Sigma-Aldrich) and human fibronectin (4 μg per well; Sigma-Aldrich). HCE-
T cells suspended in supplemented DMEM/F12 (Sigma-Aldrich) medium (Juretic et al., 2017) (105 
cells in 0.5 mL) were seeded onto the coated polycarbonate filter, and 1.5 mL of the culture medium 
was added to the basolateral side. The cells were cultivated submerged in the medium until a sharp 
increase in transepithelial electrical resistance (TEER) was observed (from 4 to 7 days), after which 
they were exposed to the air-liquid interface (ALI) for the following 3 days. The culture medium was 
changed every 2 days during the submerged conditions and every day during the exposure to the 
ALI. During the ALI exposure, the inserts were lifted on a metal plate to increase the basolateral 
volume to 2 mL. 
Before treatment with the NE samples, the medium was aspirated from the basolateral side, the 
metal plate was removed and the inserts were washed with HBSS. The inserts were then transferred 
to a new 12-well cell culture plate (Corning B.V. Life Sciences) and incubated for 30 min in HBSS (0.5 
mL apical side/1.5 mL basolateral side) at 37 °C. After incubation, HBSS from the apical side was 
removed and 0.5 mL of NE sample diluted 10 times (V/V) in HBSS pH 6.0, as previously described 
(Kinnunen et al., 2014), was added and the model was incubated for 30 min at 37 °C. HBSS only and 
ibuprofen suspension (0.2 mg mL-1) in HBSS were used as controls. All the samples were tested in 
triplicate. The pH of HBSS was set to 6.0 in order to ensure protonated form of chitosan on the NE 
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droplet surface (Rinaudo, 2016). After incubation the test samples were removed from the apical 
side, the inserts were washed with HBSS and displaced to a new 12-well plate with the metal plate 
and 2 mL of medium at the basolateral side. MTT assay was performed after 24 h according to the 
protocol by Pauly and coworkers (Pauly et al., 2009). The medium was removed and 0.7 mL of MTT 
solution in the medium (0.5 mg mL-1) was added to both apical and basolateral side and the cell 
model was incubated for 3 hours at 37 °C. Subsequently, the MTT solution was removed and 
formazan crystals were dissolved by the addition of 0.7 mL of isopropanol (Kemig) to both sides. The 
absorbance was measured at 570 nm with a microplate reader (1420 Multilabel counter VICTOR3, 
Perkin Elmer, Waltham, MA, USA). 
 
2.12.2. Ex vivo corneal biocompatibility 
Corneal biocompatibility was assessed on freshly excised porcine corneas. Briefly, fresh porcine 
eyeballs were obtained from Large White pigs (age 6-7 months, weight 90-115 kg, both female and 
male animals) from a local slaughterhouse. Porcine eyeballs were enucleated, rinsed with an isotonic 
saline solution (NaCl 0.9 %; B. Braun, Melsungen, Germany) and transported in cold KRB buffer in a 
container held on ice. After transport, the eyeballs were submerged in 1 % Betadine® solution 
(Alkaloid, Skopje, North Macedonia) for 3-5 min for microbial decontamination and subsequently 
washed with phosphate buffered saline pH 7.4 (PBS; Sigma-Aldrich) containing 1 % (V/V) 
penicillin/streptomycin/amphotericin B mixture (Cat. No. 17-745E; Lonza, Basel, Switzerland). The 
transport of porcine eyeballs and the excision of corneo-scleral buttons were performed within 2 h 
of animal death. The corneas were excised as corneo-scleral buttons in a laminar-flow hood (Thermo 
Scientific, Waltham, MA, USA) and placed with the epithelial side down on 15 mL conical centrifuge 
tube caps. 1 mL of 4 % (w/V) agar (Muller Hinton II Agar, BBL™, Becton, Dickinson and Company, 
Sparks, MD, USA) in DMEM/F-12 (Gibco®, Life TechnologiesTM, Carlsbad, CA, USA) cell culture 
medium without supplements, previously autoclaved (121 °C, 20 min) and if necessary reheated in a 
microwave to a liquid state was pipetted on endothelial side of each corneo-scleral button, in order 
to enable the formation of a naturally curved shape of the corneas. After cooling and subsequent 
gelling of the agar solution the corneo-scleral buttons were placed on a 6-well plate (endothelial side 
down) and 3.5 mL of DMEM/F-12 (Gibco®, Life Technologies™), supplemented with 10 % (V/V) FBS 
(Biosera, Boussens, France) and 10 % (V/V) penicillin/streptomycin/amphotericin B mixture was 
added to each well, so that the corneas were exposed to the air. The corneo-scleral buttons were 
left overnight in the incubator (humidified atmosphere, 5 % CO2, 37 °C) and treatment with the NE 
samples was done the following day. The medium was aspirated and custom-made silicone rings 
were placed onto the corneas. 200 µL of a test sample was added inside each ring and the corneas 
were incubated at 37 °C for 5 and 15 min. After each time-point the samples were removed, the 
corneas were washed with PBS and the extent of any corneal damage was evaluated visually with 
the aid of fluorescein solution (2 mg mL-1) in PBS and a cobalt-blue lamp (Conóptica, Barcelona, 
Spain). Briefly, the silicone rings were placed on the corneas again and 200 µL of the fluorescein 
solution was put inside and left for 20 seconds. The fluorescein solution was removed, the corneas 
were washed with PBS and photographs were taken through a yellow filter of the cobalt-blue lamp. 
PBS was used as negative control, while acetone (Sigma-Aldrich), 0.1 M NaOH solution and 0.025 % 
(w/V) benzalkonium chloride (BAK; Sigma-Aldrich) solution in PBS were used as positive controls. All 





The quantitative determination of ibuprofen was performed by UPLC using an Agilent Infinity 1290 
(Agilent) with the Acquity UPLC BEH Shield RP18 Column (1.7 μm, 2.1 mm × 50 mm) (Waters, 
Milford, MA, USA) and isocratic elution. For ibuprofen solubility study ibuprofen solutions in oil were 
diluted with methanol. The mobile phase was composed of NaH2PO4 buffer (prepared in in Milli-Q™ 
water (Merck-Millipore), 1.2 mg mL-1, pH 2.5) and acetonitrile (ACN; Merck-Millipore) in 60:40 (V/V) 
ratio. The following UPLC conditions were applied: column temperature 50 °C, flow rate 0.4 mL min-
1, injection volume 4 µL, detection wavelength 225 nm. For ibuprofen entrapment efficiency the 
filtrates were analyzed without dilution. The following UPLC conditions were applied: mobile phase 
buffer:ACN in 65:35 (V/V) ratio, column temperature 50 °C, flow rate 0.8 mL min-1, injection volume 
4 µL, detection wavelength 225 nm. For ibuprofen quantification in in vitro release samples, 
different methods were used for receptor and donor compartment sample analysis. The receptor 
compartment samples were analyzed using the same method as for ibuprofen entrapment efficiency 
analysis, with the only difference in the injection volume which was 20 µL. The donor compartment 
samples were diluted with methanol prior analysis and then analyzed with the method used for 
ibuprofen solubility study. All samples and standard solutions were filtrated through 0.2 μm 
Spartan™ regenerated cellulose filters prior analysis. For each sequence standard solutions were 
prepared in duplicate and injected alternately. At least five standard solution injections were done in 
each injection sequence. System suitability was evaluated according to the following criteria: relative 
standard deviation (RSD) of the detector response factor for all standard solution injections in the 
sequence is not more than 2.0 % and tailing factor of ibuprofen peak is not more than 1.5. The UPLC 
methods were validated in terms of linearity, accuracy and repeatability. The methods were found 
to be linear (R2 ≥ 0.99), accurate (recovery values 98-102 %) and repeatable (relative standard 
deviation of peak area (RSD) ≤ 2.0 %). 
 
2.14. Statistical analysis 
Statistical analyses were performed on the data obtained from the study on mucoadhesion and in 
vitro biocompatibility using One-way ANOVA followed by a multiple comparisons Tukey’s and 
Dunnett’s post hoc test, respectively with P < 0.05 set as the minimal level of significance. 
Calculations were performed with the GraphPad Prism software (GraphPad Software, Inc., San 
Diego, USA; www.graphpad.com). 
Ibuprofen in vitro release profiles from the tested NEs and controls were compared by the similarity 
factor (f2) calculation, as previously described (Diaz et al., 2016). The mean cumulative amounts of 
the released drug from the two formulations were compared at each time point. The release profiles 




3. Results and discussion 
Ophthalmic NEs are complex dosage forms with several physicochemical parameters, such as 
nanodroplet size, size distribution and zeta-potential, formulation viscosity profile as a function of 
applied shear, pH, osmolarity, and surface tension, affecting their in vivo performance (Qu et al., 
2018; Walenga et al., 2019). Although NEs are complex, they can be easily manufactured on a large 
scale using specific equipment, such as microfluidizers and high-pressure homogenizers, and 
sterilized by filtration or autoclavation. Formulation parameters (type and concentration of 
excipients) as well as process parameters (homogenization pressure and number of homogenization 
cycles) are the determinants of formulation physicochemical parameters, but specifically for the 
treatment of DED, formulation parameters are possibly the key determinants of formulation effect 
on the tear film stability. In clinical studies of CsA NE, a significant improvement over the baseline for 
several in vivo outcome measures was indicated for formulation without API (Simmons and Vehige, 
2007; Stevenson et al., 2000; Walenga et al., 2019). Moreover, studies that measured tear film 
breakup time (TBUT), a metric of tear film stability defined as the time from the opening of the 
eyelids to the initial dry spot formation, showed an increase in TBUT 1 h after instillation of an 
artificial tear product with composition similar to Restasis® (Simmons and Vehige, 2007). The long 
residence time of the lipid components, detected 3 to 4 h after instillation, may be the cause of 
TBUT enhancement (Stevenson et al., 2000; Walenga et al., 2019). Therefore, special emphasis 
should be placed on the selection of excipients in order to obtain a functional NE for DED treatment.  
 
3.1. Excipient and formulation considerations 
While in primary NEs oil phase is emulsified with water phase using a surfactant, in secondary NEs an 
oppositely charged polyelectrolyte is deposited over a primary NE droplet surface (Rai et al., 2018). 
To obtain positively charged secondary NEs, we selected chitosan as the positively charged 
polyelectrolyte and Lipoid S 45 lecithin as the anionic surfactant enabling interaction with chitosan 
(Hafner et al., 2009). Moreover, Lipoid S 45 lecithin is a fat-free soybean lecithin with 45 % (w/w) 
phosphatidylcholine and 10-18 % (w/w) phosphatidylethanolamine, two constituents of the natural 
tear film important for its stability. Moreover, studies suggest that lower levels of the two polar 
phospholipids are present in individuals with tear film deficiencies (Jones et al., 2017; McCulley and 
Shine, 1997; Shine and McCulley, 1998). 
The selection of the internal oil phase depends on the compatibility of the oil with lecithin and on 
the solubility of the drug in the oil, especially because the oil phase concentration in the eye drops 
should not exceed 5 % (Tamilvanan and Benita, 2004). In this study, among ophthalmically 
acceptable oils tested (castor oil, soybean oil, sesame oil), lecithin was easily soluble without heating 
only in Miglyol® 812, a medium-chain-triglyceride (MCT) oil consisting of a mixture of triglycerides of 
saturated fatty acids. Furthermore, ibuprofen was also shown to have high solubility in Miglyol® 812 
(92.7±0.2 mg g-1) and Miglyol® 812/lecithin (50:1, w/w) solution (101.3±3.3 mg g-1). 
A total of 5 NE formulations of Miglyol® 812 (5 %, w/w) and lecithin (0.1, 0.25, 0.5, 0.75 and 1 %, 
w/w) were prepared by microfluidization under the pressure of 1000 bar and 10 cycles (Table 1). The 
resulting NEs were highly fluid and homogenous with milky-white appearance, characterized with 
droplet size from 251.6 to 140.1 nm, PDI from 0.100 to 0.174 and zeta-potential from -40.1 to -48.8 
mV with increasing the amount of lecithin in the formulation. At this point, the concentration of 
lecithin adequate to render the droplets negatively charged was to be determined and, as it can be 
seen from the Table 1, all the NEs prepared had highly negative zeta-potential. The most important 
criterion in manufacturing NEs is to obtain a desired droplet size with monomodal distribution. The 
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mean droplet size expectedly decreased with the increase in the amount of lecithin, but with lecithin 
concentrations higher than 0.75 % (w/w) PDI started to increase. Even though the NE produced with 
the lowest concentration of lecithin (0.1 %, w/w) had the largest mean droplet size, it was chosen for 
further formulation development studies because its zeta-potential was already highly negative, and 
another non-ionic surfactant was to be introduced for further droplet size reduction and 
stabilization.  
It has already been demonstrated that a combination of lecithin with a second more hydrophilic 
surfactant can lead to formation of NEs with decreased droplet size and increased stability, even in 
the presence of an API (Trotta et al., 2002). Therefore, Kolliphor® EL was included as the second, 
more hydrophilic surfactant, as it is approved in ophthalmic formulations by the FDA in 
concentrations up to 5 % (FDA Database: Inactive ingredients). A total of 5 NE formulations of 
Miglyol® 812 (5 %, w/w), lecithin (0.1 %, w/w) and Kolliphor® EL (0.25, 0.5, 1, 2 and 2.5 %, w/w) were 
prepared by microfluidization (Table 2). The addition of Kolliphor® EL in NE with lecithin caused an 
expected droplet size reduction. Even though a slight increase in PDI was noticed with Kolliphor® EL 
concentrations higher than 1 % (w/w), all NEs had PDI  0.200 and were therefore considered to be 
monodisperse (Klang and Valenta, 2011). Most importantly, the addition of Kolliphor® EL had a 
major influence on NE zeta-potential; the zeta-potential values were approaching zero with the 
increase in Kolliphor® EL concentration. The presence of the non-ionic surfactant, Kolliphor® EL on 
the droplet surface probably reduced the density of negatively charged molecules from lecithin 
packed on the droplet surface. Thus, to decide which formulation should be selected for further 
studies, a compromise was made between the lowest droplet size and PDI and a zeta-potential 
negative enough to enable electrostatic interaction with positively charged chitosan molecules. NE 
with 0.5 % (w/w) Kolliphor® EL with droplet size 181.1±2.9 nm, PDI of 0.092±0.026 and zeta-
potential of -15.9±0.4 mV was chosen for further studies. 
After optimizing the formulation parameters (i.e. the concentration of lecithin and Kolliphor® EL), 
optimization of process parameters was performed. The homogenization pressure and the number 
of cycles (passes of the formulation through microfluidizer) were gradually increased and the results 
are graphically shown in Fig. S1. In accordance with previously reported data (Meleson et al., 2004; 
Uluata et al., 2016), the formulation droplet size and PDI decreased with increasing homogenization 
pressure and number of cycles, while the zeta-potential remained practically unchanged through all 
the conditions applied. However, no further droplet size (and PDI) reduction was achieved when the 
homogenization pressure was increased to 1300 bar. Therefore, the homogenization pressure of 
1000 bar was chosen for further studies. Even though only a minor droplet size reduction (3.6 nm) 
was achieved when the number of cycles under this pressure was increased from 3 to 5, we decided 
to use 5 cycles for further NE preparation to assure sufficient homogenization of the formulations. 
The same optimized formulation was prepared under the selected process parameters (1000 bar, 5 
cycles) using a high-pressure homogenizing device and similar results (droplet size, PDI, zeta-
potential) were obtained (Fig. S2), which indicates that preparation of the formulation could be 
transferable to high-energy methods other than microfluidization.  
The cationic polysaccharide chitosan was chosen to form a coating around the oil droplets making 
them positively charged and therefore mucoadhesive. The selection of chitosan was also based on 
its biocompatibility and biodegradability since it can be degraded by lysozyme which is highly 
concentrated in tears (de la Fuente et al., 2010). Additionally, the antimicrobial properties of 
chitosan could be very advantageous for patients with DED who often suffer secondary infections 
(de la Fuente et al., 2010). To obtain chitosan-coated secondary NEs, we screened the effect of 
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addition of LMw and MMw chitosan solution to the prepared NE under magnetic stirring. The final 
chitosan concentration ranged from 0.05 to 0.5 % (w/w). Since chitosan was added as 1 % (w/w) 
solution, the concentration of other NE components (oil and surfactants) decreased. To assure the 
same nanodroplet surface area available for coating with chitosan molecules, the concentration of 
Miglyol® 812 was set to 2.5 % (w/w) in all the formulations by the addition of double-distilled water 
where necessary. Chitosan-coated NEs prepared with LMw chitosan had lower droplet size and PDI 
values than those prepared with MMw chitosan (Table 3), which can be explained by a thinner 
coating layer formed by chitosan with lower Mw (Li et al., 2016). Chitosan Mw did not seem to have a 
strong influence on the final NE zeta-potential, as already reported (Mun et al., 2006). Therefore, 
LMw chitosan was chosen for further formulation optimization in low and high concentration (0.05 
and 0.3 %, w/w) resulting with zeta-potential of 29.2±0.2 and 40.3±0.9 mV, respectively. Further 
step was the addition of chitosan in the aqueous phase prior phase mixing and processing on 
microfluidizer. The comparison between chitosan-coated NEs obtained with the two different 
methods is shown in Table 4. A decrease in NE mean droplet size, zeta-potential and PDI is evident 
when chitosan is added prior processing on microfluidizer. The moment of chitosan addition to the 
formulation seemed to have a major impact on the final NE characteristics. The observed decrease in 
droplet size, PDI and zeta-potential could be a consequence of intercalation of chitosan molecules 
between surfactant molecules at the droplet surface and a mixed interfacial film formation with 
overall positive surface charge (Jumaa and Muller, 1999). The NE formulation with higher chitosan 
concentration had higher PDI, which was expected because chitosan products show a broad range of 
molecular weights (Nguyen et al., 2009). The morphological AFM analysis was performed as a 
complementary method to confirm the results obtained by PCS. The analysis pointed out spherical 
droplets with dimensions similar to those obtained with PCS measurements (Fig. 1). Thus, the 
second preparation method where the addition of chitosan to the formulation is done before 
processing on microfluidizer was used in further studies, leading to the lowest droplet size and PDI 
of chitosan-coated NEs.  
Optimized chitosan-coated NEs with 0.05 (NC1) and 0.3 (NC2) % (w/w) chitosan, and the uncoated 
control formulation (N) stored in ambient or refrigerated conditions over 30 days did not show any 
significant differences in their appearance. However, in comparison to freshly obtained formulations 
a certain decrease in PDI was observed, especially after 30-day storage at 25 °C (Fig. 2). NC1 did not 
show major changes in droplet size, but the droplet size of NC2 notably increased after 30-day 
storage at 25 °C. A small increase in zeta-potential was also observed for NC2 formulation stored at 
25 °C. Acceptable stability was further studied with special thermodynamic stability tests, which 
predict droplet integrity in case of temperature fluctuations (6 cycles of refrigeration and heat, 3 
freeze-thaw cycles) (Fig. 3). NC1 and NC2 remained visually unchanged showing no phase 
separation. Heating-cooling cycles caused certain droplet size increase in NC2 (approximately 1.6 
times), with noticeable PDI fluctuations, but without significant changes in zeta-potential. On the 
other hand, heating-cooling cycles did not cause notable changes in the formulations N and NC1 
Three freeze-thaw cycles showed negligible effect on droplet size and zeta-potential of all NEs 
tested, with certain PDI increase in NC2. Kinetic instability such as creaming, settling or any other 
form of phase separation was ruled out by centrifugation of the formulations at 9000  g. After 
centrifugation an apparent phase separation was observed in all the formulations, but after only a 
mild agitation the formulations turned uniform again, which was also confirmed by droplet size, PDI 
and zeta-potential measurements (Fig. 3). Although these stability studies demonstrated superior 
stability of NC1 over the NC2 formulation, none of the formulations showed creaming or phase 
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separation after 30-day storage or stress tests, which was the prerequisite for ibuprofen 
introduction. 
 
3.2. Loading of chitosan-coated NEs with ibuprofen and their optimization for topical 
ophthalmic administration 
In ophthalmic formulations, ibuprofen is used at low concentrations (between 0.1 and 0.2 %, w/w). 
Ibuprofen-loaded NEs were prepared by ibuprofen dissolution in the oil phase prior phase mixing 
and the final NE composition is shown in Table 5. In addition to ibuprofen incorporation in the oil 
phase, in this step of chitosan-coated NE optimization, formulation tonicity was adjusted by the 
addition of glycerol in the aqueous phase. Glycerol was chosen as the tonicity agent not to induce 
significant alterations in the physicochemical properties of the chitosan-coated NEs (Teixeira et al., 
2017) and also due to its short-lasting osmoprotective effect (Baudouin et al., 2013).  
Ibuprofen is a weak acid, BCS class II compound, and its molecules are well encapsulated into the oil 
droplets due to the hydrophobic character of the drug (Gue et al., 2016). Ibuprofen entrapment 
efficiency was higher than 98 % in all the NEs (Table 6). Droplet size and PDI remained similar after 
ibuprofen incorporation, but the zeta-potential of chitosan-coated INC1 and INC2 formulations was 
slightly higher than for unloaded NC1 and NC2 formulations (Table 6). In vivo performance of 
ophthalmic NEs is further affected by the formulation pH, surface tension and viscosity profile as the 
function of the applied shear. The pH of all the chitosan-coated NE formulations was around 4.5 
regardless of ibuprofen incorporation (Table 6), due to the acetic acid addition necessary to dissolve 
chitosan. Wide pH range can be tolerated by the ocular surface, especially when the ophthalmic 
product is not buffered (Lang et al., 2005; Fialho and da Silva-Cunha, 2004). A study performed on 6 
healthy volunteers showed that immediately after the instillation of 20 µl of 0.067 M phosphate-
buffered saline, pH 5.5, the pH value of the tear film was found to be about 6.0–6.5 and that the tear 
film rapidly became more alkaline, reaching pH 7 in about 1 min, and approximately its normal value 
in an additional 1–1.5 min (Yamada et al., 1998) It is generally accepted that low pH of an 
ophthalmic product will not necessarily cause stinging or discomfort upon instillation if the pH of the 
tears can be rapidly brought back to normal values (Lang et al., 2005), but data about the buffering 
capacity of tears in DED are lacking. However, there are studies that indicate slightly higher pH of 
tears of participants with DED (Khurana et al., 1991; Norn, 1988). Even though DED patients often 
have lower tear volume, this alkaline shift might be a compensatory mechanism to return the pH of 
tears to more neutral values after instillation of an acidic ophthalmic product, as it is the case with 
chitosan-coated NEs. 
Surface tension is an important physicochemical formulation parameter that determines spreading 
of a formulation across the ocular surface and also influences capillary drainage through the 
nasolacrimal ducts, affecting precorneal residence time of the instilled formulation. All the surface 
tension measurements were carried out at the eye drop application temperature, i.e. 25 °C, to be 
comparable with the tear film surface tension values reported, which were also measured at 25 °C. 
Chitosan and ibuprofen both induced a decrease in the formulation surface tension (Table 6). 
Surface active properties of chitosan are well-known, as it can be used as an O/W emulsion stabilizer 
(Payet and Terentjev, 2008). Ibuprofen surface active properties have also been confirmed (Baydoun 
et al., 2004; Rao et al., 1992) and are probably the reason for additional surface tension decrease 
when ibuprofen was introduced to the chitosan-coated NEs. The surface tension at the air interface 
of the preocular tear film has physiological range of 40–46 mN m-1, while in DED the characteristic 
range is approximately 44–53 mN m-1 (Nagyova and Tiffany, 1999). In general, higher surface tension 
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values coincide with lower tear film stability, but the scarce literature data reported that the eye 
drops with a surface tension below 35 mN m-1 are painful and uncomfortable (Hotujac Grgurevic et 
al., 2017; Ludwig and Reimann, 2015). Higher concentration of chitosan in the INC2 formulation 
pushed the surface tension slightly below this limit.  
Viscosity profile as the function of the applied shear showed a Newtonian fluid behavior of the NEs. 
The measured viscosity values were similar to the viscosity of water, with a slight increase with the 
addition of chitosan (1.1–4.1 mPas, Table 6). The measured viscosity values were in the physiological 
range of a human tear film (1–9 mPas) (Pandit et al., 1999; Tiffany, 1991), which has been proposed 
as the desirable viscosity range for the artificial tears that follow Newtonian behaviour (Acar et al., 
2018). Moreover, low formulation viscosity enables dosing accuracy and ease of eye-drop 
administration. 
Tear film hyperosmolarity plays etiological role in DED and osmoprotectants could provide necessary 
protection of cells under extreme osmotic stress by balancing the osmotic pressure without 
disturbing cell metabolism (Jones et al., 2017). Osmolarity of all ibuprofen-loaded NEs was in the 
osmolarity range of a normal tear film (Table 6), i.e. between 270 and 315 mOsm kg-1 (Willcox et al., 
2017). 
After 30-day storage at 4 °C INC1 and the control chitosan-uncoated formulation IN showed only a 
minor droplet size increase of 8.2 and 5.3 nm, respectively, while PDI and zeta-potential values 
remained unchanged or very similar (INC1: 0.127±0.016, 22.8±2.3 mV; IN: 0.101±0.008, -12.2±1.8 
mV). However, a significant droplet size increase of 35.3 nm (18 %) was noted for INC2 formulation, 
while its PDI and zeta-potential remained quite similar to those of the freshly-prepared INC2 
formulation (0.323±0.034, 38.9±1.4). Overall, it seems that the addition of ibuprofen caused a 
detectable instability of the INC2 formulation. On the contrary, stability of the INC1 formulation with 
lower chitosan concentration was not compromised. The pH of all the formulations remained 
practically unchanged after 30-day storage at 4 °C (data not shown).  
Altogether, the results obtained from physicochemical characterization pointed out INC1 as the 
formulation with all the physicochemical properties within the acceptable range for ophthalmic use. 
The INC1 droplet size, zeta-potential, viscosity, osmolarity and surface tension resemble the values 
reported for NEs produced using Novasorb® technology (Lallemand et al., 2012). In addition, the 
INC1 formulation was found to be stable under all the experimental conditions tested. 
 
3.3. Sterilization 
Sterility is a basic requirement for ophthalmic NEs and filtration and/or autoclavation are usually 
used for sterilization of the final product. Clearly, elevated temperatures during the autoclavation, 
can seriously affect the final NE physicochemical characteristics. Autoclavation can cause hydrolysis 
of some lipids and lecithins, resulting in liberation of free fatty acids, which can compromise NE 
stability. Furthermore, it has already been reported that the autoclaving process can lead to 
destabilization of chitosan-coated lipid emulsions (Jumaa and Muller, 1999), which could be 
explained by temperature induced chitosan interchain crosslinking involving the amino groups (Lim 
et al., 1999). Indeed, autoclavation of the chitosan-coated NEs (NC1, NC2, INC1 and INC2) at 121 °C 
during 20 minutes resulted in meaningful changes in both physicochemical properties (increase in 
droplet size and PDI, reduction of zeta-potential, Fig. 4) and visual appearance (change in color and 
creaming). In contrast, NEs without chitosan (N and IN) showed satisfying stability after the 
autoclaving process regarding their droplet size, PDI and zeta-potential. However, filtration of 
chitosan-coated NEs through PES filters with 0.2 µm pore size did not affect any of the parameters 
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tested (Fig. 4), as reported previously (Gue et al., 2016). Therefore, the final chitosan-coated NEs can 
be easily sterilized by aseptic filtration through a sterilizing membrane into a sterile suite (Floyd, 
1999), without the need for aseptic preparation procedure. 
 
3.4. In vitro ibuprofen release 
In general, drug release from a NE involves partitioning of the drug from the oil droplets into the 
surfactant layer and then into the aqueous phase (Singh et al., 2017). While diffusing out from the 
oil, the drug comes in contact with the surrounding aqueous media and depending on its solubility 
and the volume of the aqueous media it can undergo nanoprecipitaion. Biorelevant methods for in 
vitro release testing of ophthalmic products are still in development (Jug et al., 2018). In vitro drug 
release from nano-sized ophthalmic delivery system is currently assessed using a variety of 
membrane diffusion techniques including simple dialysis methods, dialysis methods using modified 
Apparatus 1 or 2 as well as Franz diffusion cells (Jug et al., 2018). We chose a dialysis method using 
modified Apparatus 2, and since the concentration of ibuprofen present in the NE formulations 
exceeds ibuprofen water solubility (Hussain et al., 2018), a commercially available ibuprofen oral 
suspension (20 mg mL-1; Neofen®, Belupo, Croatia), diluted with double-distilled water to the 
appropriate concentration, and ibuprofen oil (Miglyol® 812) solution were used as controls. The 
obtained in vitro release profiles are shown in Fig. 5. About 90 % of ibuprofen was released from the 
NEs in 120 min. The t50% of IN, INC1 and INC2 was 30, 35 and 41 min, respectively. Unsurprisingly, 
ibuprofen release was significantly faster from the NE formulations than from the ibuprofen 
suspension (t50% = 68 min; f2 < 45) and oil solution (t50% = 94 min; f2 < 30), due to the large total 
nanodroplet surface area available for drug diffusion in the NEs. Such a release profile could be 
beneficial regarding the limited drug residence at the ocular surface. The addition of chitosan to the 
NE formulation seemed to slightly slow down ibuprofen release, but the statistical significance was 
confirmed only between IN and INC2 formulations (f2 = 48). This could be explained by localisation of 
chitosan molecules on the NE droplet surface, forming a certain barrier to ibuprofen release. 
 
3.5. Chitosan-coated NE mucoadhesive properties 
Mucoadhesive interactions between chitosan and mucin are complex and involve electrostatic 
attraction, hydrogen bonding, and hydrophobic effects (Sogias et al., 2008). The relative 
contributions of each physical interaction depend on the pH and ionic strength of the surrounding 
medium (Ding et al., 2019). Mucoadhesive properties of the chitosan-coated NEs were assessed by 
determining rheological behavior of mixtures of mucin dispersions in STF with the NE formulations 
(Hassan and Gallo, 1990). In this method, NEs were mixed with mucin dispersion in STF and a 
synergistic viscosity increase caused by interactions between NEs and mucin chains was recorded 
and calculated as ηb, according to Eq. (2). Interestingly, even anionic NE without chitosan (IN) 
showed mucoadhesive behavior, as the calculated ηb value was around 30 mPas (Fig. 6). Chitosan-
coated INC1 and INC2 formulations, on the other hand, showed significantly stronger mucoadhesion 
(INC1: P=0.0210; INC2: P=0.0184), having ηb of around 48 mPas, due to the well-known electrostatic 
interactions between positively charged chitosan molecules and negatively charged mucin chains 
(Sogias et al., 2008). However, there was no statistically significant difference between ηb of INC1 
and INC2 formulations (P=0.9927), indicating that higher chitosan concentration was not able to 
augment the effect of mucoadhesion of the NEs tested within this research.  
 




3.6.1. In vitro corneal biocompatibility 
An important aspect of topical ophthalmic formulation characterization is the investigation of 
formulation biocompatibility with the corneal epithelium. Although biocompatibility of chitosan is 
well-known, and it has been widely used in nanosystems investigated for topical ocular application, a 
concentration-dependent toxicity effect has been reported (de la Fuente et al., 2010; Diebold et al., 
2007). Also, surfactants are able to non-specifically partition into the plasma membrane causing 
membrane fluidization, which is associated with the concentration-dependent increase in 
permeability but also toxicity, due to epithelial abrasion (Brayden et al., 2014). Even though 
surfactants have a long history of use in ophthalmic drug delivery and in this study surfactants 
normally present in the tear film as well as other ophthalmically acceptable formulation components 
were used, safety has to be evaluated in vitro. The most extensively characterized human-derived 
cell line used in corneal biocompatibility and transcorneal permeability studies is the immortalized 
human corneal epithelial cell line (HCE-T) (Juretic et al., 2017). The majority of in vitro 
biocompatibility screenings is currently undertaken using cells cultured in a two-dimensional (2D) 
environment (Fitzgerald et al., 2015). However, this does not accurately reflect the three-
dimensional (3D) structure of corneal epithelium. The use of inadequate experimental tools can lead 
to wrong conclusions about formulation biocompatibility (Krtalic et al., 2018). Using 3D cell-based 
models it is possible to predict biocompatibility in vivo more closely than with the conventional 2D 
models because 3D models have more realistic representation of the tissue complexity, including 
drug, oxygen and nutrient gradients. Therefore, to test corneal epithelium biocompatibility we 
employed 3D HCE-T cell-based model. HCE-T corneal model viability was evaluated by colorimetric 
MTT assay after 30-min incubation with the NE samples and it was expressed as the percentage of 
mitochondrial dehydrogenase activity, using the cells treated with HBSS as the reference point (100 
% of mitochondrial dehydrogenase activity). As it can be seen from Fig. 7, the viability of the cells 
treated with ibuprofen suspension (IBU S) decreased to about 85 %, which is significantly lower than 
the viability of the control cells (P=0.0004). Ibuprofen loaded formulations IN and INC1 (and the 
unloaded control formulations N and NC1), on the other hand, did not significantly affect viability of 
the cells. This can be explained by ibuprofen encapsulation into the oil nanodroplets, hindering its 
direct toxicity effect on the cells. However, the formulation INC2 and the control unloaded 
formulation NC2 showed significantly lower cell viability of 93 % (P=0.0365) and 88 % (P=0.0004), 
respectively. Taking everything into account, this small but significant viability decrease could be 
ascribed to higher concentration of chitosan (0.3 %, w/w) in INC2 and NC2 formulations, which is in 
agreement with previously reported concentration-dependent toxicity of chitosan (Diebold et al., 
2007).  
3.6.2. Ex vivo corneal biocompatibility 
To confirm the data obtained from the in vitro model, biocompatibility was also tested on the ex vivo 
model using freshly excised porcine corneas. The corneas were incubated with NEs during 5 and 15 
min and the extent of corneal damage was evaluated visually using fluorescein solution and a cobalt 
blue lamp, since fluorescein staining is a well-known measure of corneal epithelial cell damage 
(Prinsen and Koeter, 1993). Photographs were taken after each incubation time point and they are 
shown in Fig. 8. While PBS (negative control) and ibuprofen suspension (IBU S; 0.2 %, w/V) did not 
cause corneal epithelial damage, an intense staining was observed after incubation with 0.1 M NaOH 
solution and acetone (positive controls). Fluorescein staining was also observed on BAK treated 
corneas after 15-min incubation. BAK was applied as 0.025 % (w/V) solution in PBS, since it is the 
18 
 
highest concentration approved in the eye drops (FDA Database: Inactive ingredients). It can clearly 
be seen that IN and INC1 formulations did not cause any changes on the corneal surface since no 
fluorescein staining was detected, but the INC2 formulation caused a mild fluorescein staining after 
15-min incubation, which is in agreement with the in vitro studies performed. 
 
3.7. Conclusions 
Herein we propose chitosan-coated NEs for improved NSAIDs delivery in the treatment of mild-to-
moderate DED. The results of our study pointed out INC1 as the lead formulation, having 
physicochemical properties inside the appropriate range for ophthalmic application, adequate 
stability and the possibility to be easily sterilized after preparation. Also, the proposed formulation 
has significant mucoadhesive character, as confirmed by the in vitro studies, and excellent 
biocompatibility, which was tested on two models, namely 3D HCE-T cell-based model and ex vivo 
model using fresh porcine corneas. Development of formulations with prolonged residence at the 
ocular surface would enable reduction of the required NSAID dose providing better benefit-risk 
balance of future ophthalmic drug products. In addition, ibuprofen-free NC1 formulation could also 
be used as a drug-free vehicle (artificial tears) for symptomatic treatment of mild-to-moderate DED. 
However, further in vivo studies are necessary to confirm these conclusions. 
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Table 1. Droplet size, PDI and zeta-potential of NEs with 5 % (w/w) Miglyol® 812 and 
increasing amounts of lecithin. 
Lecithin (%, w/w) Droplet size (nm) PDI Zeta-potential (mV) 
0.1 251.6±1.6 0.100±0.016 -40.1±1.5 
0.25 220.1±2.4 0.089±0.018 -44.9±1.3 
0.5 184.8±1.2 0.116±0.008 -46.9±1.0 
0.75 160.1±1.9 0.112±0.010 -48.9±1.2 
1.0 140.1±2.5 0.174±0.048 -48.8±1.2 
Values are mean  SD (n = 2). 
Table 2. Droplet size, PDI and zeta-potential of NEs with 5 % (w/w) Miglyol® 812, 0.1 % 
(w/w) lecithin and increasing amounts of Kolliphor® EL. 
Kolliphor® EL (%, 
w/w) 
Droplet size (nm) PDI Zeta-potential (mV) 
0.25 212.3±3.8 0.112±0.017 -20.7±0.7 
0.5 181.1±2.9 0.092±0.026 -15.9±0.4 
1.0 138.6±1.8 0.108±0.017 -13.0±0.4 
2.0 99.1±1.9 0.176±0.019 -6.2±0.6 
2.5 83.6±1.2 0.201±0.018 -3.6±0.3 
Values are mean  SD (n = 2). 
Table(s)
Table 3. Droplet size, PDI and zeta-potential of NEs with 2.5 % (w/w) Miglyol® 812, 0.05 % 
lecithin, 0.25 % (w/w) Kolliphor® EL and different chitosan (low (LMw) and medium 
molecular weight (MMw)) concentrations. 













0.05 199.6±1.6 0.072±0.002 29.2±0.2 255.9±44.7 0.240±0.066 31.8±1.3 
0.1 199.3±4.5 0.138±0.052 32.7±0.1 282.6±9.6 0.305±0.003 35.3±1.0 
0.2 279.0±28.4 0.288±0.001 37.4±0.0 418.7±139.3 0.652±0.039 38.9±1.6 
0.3 360.9±14.7 0.489±0.013 40.3±0.9 583.7±36.1* 0.841±0.023 41.4±2.4 
0.4 390.1±27.4 0.504±0.014 39.0±0.5 626.8±74.3* 0.853±0.065 42.2±2.2 
0.5 325.7±15.0 0.535±0.070 42.7±1.6 749.4±27.7* 0.791±0.175 44.0±2.0 
Values are mean  SD (n = 2). 
*The result may not represent the real mean value due to very high PDI (˃ 0.7). 
 
Table 4. Comparison of LMw chitosan coated NEs prepared with two different methods 
described in the section 2.3.2. 
 
Chitosan added after microfluidization Chitosan added before phase mixing 












0.05 199.6±1.6 0.072±0.002 29.2±0.2 179.3±2.3 0.061±0.015 18.7±1.9 
0.3 360.9±14.7 0.489±0.013 40.3±0.9 179.3±7.6 0.169±0.011 30.0±1.5 
Values are mean  SD (n = 2). 
 
























N - - 2.5 0.05 0.25 2.5 94.7 
IN 0.2 - 2.5 0.05 0.25 2.5 94.5 
NC1 - 0.05 2.5 0.05 0.25 2.5 94.65 
INC1 0.2 0.05 2.5 0.05 0.25 2.5 94.45 
NC2 - 0.3 2.5 0.05 0.25 2.5 94.4 
INC2 0.2 0.3 2.5 0.05 0.25 2.5 94.2 
Table 6. Ibuprofen-loaded NEs characterized in terms of droplet size, PDI, zeta-potential, 
entrapment efficiency, pH, viscosity, osmolarity and surface tension. 
 































































Figure 1. AFM images of NC2 formulation (0.3 %, w/w LMw chitosan, 2.5 %, w/w Miglyol® 812, 0.05 
%, w/w lecithin and 0.25 %, w/w Kolliphor® EL): a) 2D topography (5x5 µm scan area); b) 3D 
topography (5x5 µm scan area); c) and d) profiles of two representative NE droplets marked on the 
2D topography a). 
 
Figure 2. Droplet size, PDI and zeta-potential of chitosan-coated NEs with 0.05 (NC1) and 0.3 (NC2) % 
(w/w) chitosan, and the uncoated control formulation (N) measured after preparation and 30-day 
storage at 4 or 25 °C. NEs were prepared by adding chitosan to water phase before phase mixing and 
microfluidization. Data are expressed as mean ± SD (n = 2-3). 
 
Figure 3. Droplet size, PDI and zeta-potential of chitosan-coated NEs with 0.05 (NC1) and 0.3 (NC2) % 
(w/w) chitosan, and the uncoated control formulation (N) measured before and after stress tests 
(heating-cooling cycles, centrifugation and freeze-thaw cycles). Data are expressed as mean ± SD (n = 
2-3). 
 
Figure 4. Droplet size, PDI and zeta-potential of chitosan-coated NEs with 0.05 % (w/w) chitosan and 
loaded with ibuprofen (INC1) or ibuprofen free (NC1), chitosan-coated NEs with 0.3 % (w/w) 
chitosan and loaded with ibuprofen (INC2) or ibuprofen free (NC2), the uncoated control 
formulation loaded with ibuprofen (IN) or ibuprofen free (N) measured before and after autoclaving 
(121 °C/20 min) or filtration (PES; 0.2 µm). Data are expressed as mean ± SD (n = 2).  
 
Figure 5. In vitro release profiles of ibuprofen from chitosan-coated NEs with 0.05 (INC1) and 0.3 
(INC2) % (w/w) chitosan, the uncoated control formulation (IN) and respective controls (ibuprofen 
oil solution and ibuprofen suspension) tested during 6 hours (360 minutes) in phosphate buffer pH 
7.4 at 34 °C. Data are expressed as mean ± SD (n = 3-6). 
 
Figure 6. Mucoadhesive properties of ibuprofen-loaded NEs determined rheologically after mixing 
with 20 % (w/w) mucin dispersion in STF, expressed as the viscosity component due to bioadhesion 
(ƞb). Data are expressed as mean ± SD (n = 3). *Differs from the uncoated IN formulation (P < 0.05). 
 
Figure 7. In vitro 3D HCE-T model viability (%) determined by MTT assay after 30-min incubation with 
NE formulations (or ibuprofen suspension; IBU S) diluted 10 times (V/V) in HBSS pH 6.0. The cells 
incubated in HBSS pH 6.0 were used as control of 100 % cell viability. Data are expressed as mean ± 





Figure 8. Representative photographs of ex vivo model of porcine corneas captured after 5 and 15-
minute treatment with ibuprofen-loaded NEs (IN, INC1 and INC2) or control samples (PBS pH 7.4, 0.1 
M NaOH, aceton, 0.025 %, w/V benzalkonium chloride solution (BAK) and 0.2 %, w/V ibuprofen 
suspension (IBU S)) and subsequent fluorescein staining with the aid of a cobalt-blue lamp used to 
intensify the fluorescence signal (n  4). 
 
 
 
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
